PATENT CLAIM ANALYSIS

Application Number: 16018847
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "266400"]

Abstract:
This application describes the use of the compound or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed.

Claim (Index 28):
A method of treating non-small cell lung cancer in a subject, the method comprising administering to the subject a combination of (i) erlotinib or gefitinib, and (ii) a compound having the structure of: or a pharmaceutically acceptable salt thereof, wherein the non-small cell lung cancer is resistant or insensitive to treatment with one or more EGFR inhibitors.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907514', '15451960', '14824750', '14474928', '15146164']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.756588594895451
- 35 USC 102 Novelty (BERT): 0.5580234821972928
- Combined Prediction Score: 0.7367320836256352
- Mean Citation Score: 293.643206
- Max Citation Score: 443.681
- Similarity Product: 330.4468261560202

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test